Answers are grounded in this paper and cite their sources.
Roughly 50% of newly diagnosed multiple myeloma (MM) cases harbor KRAS (25%) or NRAS (24%) mutations with an even greater frequency of these mutations observed at relapse. By and large, mutant RAS-driven MM is more resistant to existing therapies including proteasome inhibitors, immunomodulator drugs (IMiDs), and monoclonal anti-CD38 antibodies. In the present study, we demonstrate that mutant RAS-dependent macropinocytosis (MP) can be leveraged for selective delivery of a monobody-drug conjugate (MDC) to mutant RAS MM cells. This MDC delivery platform consists of monobody, a fragment of human fibronectin (FN), used as the carrier to which monomethyl auristatin E (MMAE) is site-specifically conjugated (FN-MMAE). In comparison to standard of care (SoC) therapeutics, FN-MMAE displays a substantially improved anti-tumor effect in vitro and in vivo when administered alone or in combination with SoC treatments. Furthermore, the in vivo safety profile of FN-MMAE is tolerable affording increased drug dosing compared to clinically used ADCs. This MDC platform offers a way of selectively targeting mutant RAS MM and RRMM to potentially improve patient outcomes. Statement of Significance Ras mutations are present in approximately 50% of MM patients and are associated with poor prognosis and drug resistance. Herein, we describe a novel protein-drug conjugate designed to target selectively mutant RAS harboring MM cells. Our findings uncover a new therapeutic modality for improving the outcomes for patients with mutant Ras MM.
No takes yet. Share an insight, caveat, or question.
Beals et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: